TOKYO, Aug. 20 /PRNewswire/ — YAKULT HONSHA CO., LTD. announced
on August 20 that its collaborative study on the incidence of acute
diarrhea with the National Institute of Cholera and Enteric
Diseases in Kolkata, India, showed that daily intake of “Yakult” is
efficacious in reducing the incidence of diarrhea in young
An unprecedented large-scale study, involving 3,585 children
residing in an urban slum community in Kolkata, was conducted. As a
result, “Yakult” was shown to be efficacious in reducing the
incidence of acute diarrhea in young children and the difference
was statistically significant. The demonstration that the continued
intake of “Yakult” is effective in improving the gastrointestinal
symptoms of the general public strongly corroborates the
significance of drinking “Yakult.”
These results were published on the “Epidemiology and Infection”
website and the ePub is available on PubMed.
YAKULT HONSHA is engaged in research on probiotics, which refer
to living microorganisms that confer a benefit on the host (people,
etc.) by improving the balance of intestinal flora. A
representative probiotic strain is Lactobacillus casei strain
Shirota (YIT9029), which, in addition to an intestinal regulation
action, has been verified in many published papers to have
immunoregulatory actions such as helping to suppress the recurrence
of superficial bladder cancer and reduce allergy symptoms.
Hereafter, YAKULT HONSHA will continue to actively promote research
on utilizing the remarkable power of microorganisms for the benefit
of people’s health.
Overview of Study
The number of children aged 5 years and under that die annually
throughout the world is 8.80 million, and the country that has the
most deaths is India (approximately 1.83 million children per
year). It is reported that diarrhea is the cause in 13% of the
deaths in children aged 5 years and under in India (Black RE et al,
Lancet. 2010. 375: 1969-1987).